TKT Announces Proposed Offering Of Senior Convertible Notes Due 2011
28 4월 2004 - 6:00AM
PR Newswire (US)
TKT Announces Proposed Offering Of Senior Convertible Notes Due
2011 CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ --
Transkaryotic Therapies, Inc. today announced its intention to
publicly offer $80 million principal amount of senior convertible
notes due 2011. The company would grant to the underwriters an
overallotment option to purchase an additional $12 million
principal amount of the notes within 30 days after the offering. JP
Morgan Securities Inc. will be the sole book-running manager for
the offering, SG Cowen & Co., LLC will be the joint lead
manager for the offering and Pacific Growth Equities, LLC and RBC
Capital Markets will be co- managers. A shelf registration
statement relating to the notes that the company intends to sell
has previously been filed with, and declared effective by, the
Securities and Exchange Commission. Any offer, if at all, will be
made only by means of a prospectus and a prospectus supplement. A
copy of the prospectus and prospectus supplement related to the
offering can be obtained when available from the Prospectus
Department of JP Morgan Securities Inc., One Chase Manhattan Plaza,
Floor 5b, New York, NY 10081. The securities may not be sold nor
may offers to buy be accepted prior to the time that the prospectus
supplement is final. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state. About
TKT Transkaryotic Therapies, Inc. is a biopharmaceutical company
primarily focused on researching, developing and commercializing
treatments for rare diseases caused by protein deficiencies. Within
this focus, the company markets Replagal(TM), an enzyme replacement
therapy for Fabry disease, and is developing treatments for Hunter
syndrome and Gaucher disease. Outside its focus on rare diseases,
TKT intends to commercialize Dynepo(TM), its Gene- Activated(R)
erythropoietin product for anemia related to kidney disease, in the
European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe,
Canada and Latin America. Gene-Activated(R) is a registered
trademark and Replagal(TM) is a trademark of Transkaryotic
Therapies, Inc. Dynepo(TM) is a trademark of Aventis
Pharmaceuticals, Inc. CONTACTS: Justine E. Koenigsberg Director,
Corporate Communications (617) 349-0271 Daniella M. Lutz Corporate
Communications Specialist (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Justine E. Koenigsberg, Director, Corporate
Communications, +1- 617-349-0271, or Daniella M. Lutz, Corporate
Communications Specialist, +1- 617-349-0205, both of TKT Web site:
http://www.tktx.com/ Company News On-Call:
http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Transkaryotic Therapies (NASDAQ:TKTX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Transkaryotic Therapies (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Transkaryotic (MM) News Articles